Read Books Online and Download eBooks, EPub, PDF, Mobi, Kindle, Text Full Free.
Download Cabazitaxel In Castration Resistant Prostate Cancer With Brain Metastases full books in PDF, epub, and Kindle. Read online Cabazitaxel In Castration Resistant Prostate Cancer With Brain Metastases ebook anywhere anytime directly on your device. Fast Download speed and no annoying ads. We cannot guarantee that every ebooks is available!
Author : Sabino De Placido
Publisher :
ISBN 13 :
Total Pages : 4 pages
Book Rating : 4.:/5 (894 download)
Download or read book Cabazitaxel in Castration Resistant Prostate Cancer with Brain Metastases written by Sabino De Placido and published by . This book was released on 2014 with total page 4 pages. Available in PDF, EPUB and Kindle. Book excerpt:
Author : Ovidio Fernández
Publisher :
ISBN 13 :
Total Pages : 7 pages
Book Rating : 4.:/5 (876 download)
Download or read book Metastatic Castration-resistant Prostate Cancer, Changing Landscape with Cabazitaxel written by Ovidio Fernández and published by . This book was released on 2013 with total page 7 pages. Available in PDF, EPUB and Kindle. Book excerpt:
Author : Adam S. Kibel
Publisher : Elsevier Health Sciences
ISBN 13 : 1455747238
Total Pages : 184 pages
Book Rating : 4.4/5 (557 download)
Download or read book Castration Resistant Prostate Cancer, An Issue of Urologic Clinics written by Adam S. Kibel and published by Elsevier Health Sciences. This book was released on 2012-11-28 with total page 184 pages. Available in PDF, EPUB and Kindle. Book excerpt: Castrate Resistant Prostate Cancer is advanced disease that has stopped responding to hormone therapy. This issue of the Urologic Clinics focuses on the various forms of therapy including immunotherapy, first line chemotherapy, and novel targeted agents. Articles on defining the diseae and palliative care are also included.
Author : Yoichi Arai
Publisher : Springer
ISBN 13 : 981107013X
Total Pages : 420 pages
Book Rating : 4.8/5 (11 download)
Download or read book Hormone Therapy and Castration Resistance of Prostate Cancer written by Yoichi Arai and published by Springer. This book was released on 2018-05-11 with total page 420 pages. Available in PDF, EPUB and Kindle. Book excerpt: This comprehensive reference expounds the current state of hormone therapy and castration resistance of prostate cancer (PCa). Previously, the incidence of PCa in Asian countries was relatively low, but it has been increasing dramatically in recent years. Although most of the new cases are diagnosed in early stages, a significant proportion of patients receive hormone therapy for metastatic disease or for relapse after local treatment. Thus the situation has gradually changed toward earlier and longer use of hormone therapy. The malignancy finally forms castration-resistant prostate cancer (CRPC) despite the lack of testicular androgen. With advances in understanding of the molecular basis of hormone dependence and CRPC, many new androgen receptor-targeted agents have emerged. During the last decade, much evidence on hormone therapy has been accumulated in Japan. Interestingly, some of these findings are different from those reported from Western countries, suggesting ethnic variation in the outcome of hormone therapy. In the chapters of this book, expert authors provide exhaustive interpretations of the evidence recently reported from Japan and provide important Asian perspectives on hormone therapy for PCa. This work benefits not only Asian urologists but also their Western counterparts and all physicians and medical personnel who are involved in the treatment of PCa.
Author : Jou00e3o Vasco Barreira
Publisher :
ISBN 13 :
Total Pages : pages
Book Rating : 4.:/5 (116 download)
Download or read book Cabazitaxel in Patients with Castration-resistant Prostate Cancer written by Jou00e3o Vasco Barreira and published by . This book was released on 2017 with total page pages. Available in PDF, EPUB and Kindle. Book excerpt: Background: Prostate cancer (CaP) is among the most common cancers in males. Although most cases of prostate cancer are diagnosed and treated while disease is localized, some men have evidence of metastatic prostate cancer. Contemporary research has led to the development of multiple active treatment modalities for men with advanced disease, in addition to androgen deprivation therapy (ADT). Management of men with metastatic castration-resistant prostate cancer (mCRPC) involves the sequential use of these approaches, with the goals of prolonging survival, minimizing complications, and maintaining quality of life. CaP is androgen dependent in the beginning, but as time progresses, it becomes refractory to androgen deprivation treatment. At this stage, docetaxel has been used as standard treatment for years. Cabazitaxel has become the first chemotherapeutic agent which has been shown to increase survival for patients (pts) with mCRPC that progresses after docetaxel. The correlation of the oncological outcomes of pts age in mCRPC pts have not been unclear. Materials and Methods: In this study, we evaluated a total of 16 pts who progressed despite docetaxel treatments, had ECOG performance score between 0-2, and used cabazitaxel treatment 25 mg/m2 at every 3 weeks, and prednisolone 5 mg twice a day for mCRPC diagnosis in Centro Hospitalar Universitu00e1rio Lisboa Central from June 2016 to June 2019, retrospectively. We assessed the prognostic significance of cabazitaxel, focusing on pts age and the correlation of efficacy between docetaxel and cabazitaxel. Demographic and clinical data were collected and the information was cross-checked with that of the pharmaceutical services. Significance (p) of less than 0.05 was considered statistically significant. Statistical analysis was performed in Stata.Results: The median overall survival (OS) periods after the introduction of cabazitaxel was 10,4 months. A 30% PSA response to cabazitaxel was achieved in 13 (81%) pts. A 30% PSA response to cabazitaxel was achieved in 3 (50.0%) pts with u226775 years (n = 6) and 6 (60%) pts with less than 75 years (n = 10). There was no significant correlation between the PSA response and ptsu2019 age (p = 0.093). A 30% PSA response to cabazitaxel was achieved in 9 (56%) and 4 (25%) pts with and without that to docetaxel, respectively. There was no significant correlation of the PSA response between docetaxel and cabazitaxel (p = 0.087). Univariate and multivariate analysis revealed that there were no significant correlation of pts age, the response to prior docetaxel therapy or cycles of docetaxel therapy with shorter OS. Conclusions: These results suggest that cabazitaxel is a safe and effective treatment option for mCRPC pts who progress after docetaxel and indicate that the introduction of cabazitaxel for mCRPC pts could result in oncological outcomes without any association with ptsu2019s age and the profiles of previous docetaxel therapy.
Author : João Vasco Barreira
Publisher :
ISBN 13 :
Total Pages : 0 pages
Book Rating : 4.:/5 (134 download)
Download or read book Cabazitaxel in Patients with Castration-resistant Prostate Cancer written by João Vasco Barreira and published by . This book was released on 2017 with total page 0 pages. Available in PDF, EPUB and Kindle. Book excerpt: Background: Prostate cancer (CaP) is among the most common cancers in males. Although most cases of prostate cancer are diagnosed and treated while disease is localized, some men have evidence of metastatic prostate cancer. Contemporary research has led to the development of multiple active treatment modalities for men with advanced disease, in addition to androgen deprivation therapy (ADT). Management of men with metastatic castration-resistant prostate cancer (mCRPC) involves the sequential use of these approaches, with the goals of prolonging survival, minimizing complications, and maintaining quality of life. CaP is androgen dependent in the beginning, but as time progresses, it becomes refractory to androgen deprivation treatment. At this stage, docetaxel has been used as standard treatment for years. Cabazitaxel has become the first chemotherapeutic agent which has been shown to increase survival for patients (pts) with mCRPC that progresses after docetaxel. The correlation of the oncological outcomes of pts age in mCRPC pts have not been unclear. Materials and Methods: In this study, we evaluated a total of 16 pts who progressed despite docetaxel treatments, had ECOG performance score between 0-2, and used cabazitaxel treatment 25 mg/m2 at every 3 weeks, and prednisolone 5 mg twice a day for mCRPC diagnosis in Centro Hospitalar Universitu00e1rio Lisboa Central from June 2016 to June 2019, retrospectively. We assessed the prognostic significance of cabazitaxel, focusing on pts age and the correlation of efficacy between docetaxel and cabazitaxel. Demographic and clinical data were collected and the information was cross-checked with that of the pharmaceutical services. Significance (p) of less than 0.05 was considered statistically significant. Statistical analysis was performed in Stata.Results: The median overall survival (OS) periods after the introduction of cabazitaxel was 10,4 months. A 30% PSA response to cabazitaxel was achieved in 13 (81%) pts. A 30% PSA response to cabazitaxel was achieved in 3 (50.0%) pts with u226775 years (n = 6) and 6 (60%) pts with less than 75 years (n = 10). There was no significant correlation between the PSA response and ptsu2019 age (p = 0.093). A 30% PSA response to cabazitaxel was achieved in 9 (56%) and 4 (25%) pts with and without that to docetaxel, respectively. There was no significant correlation of the PSA response between docetaxel and cabazitaxel (p = 0.087). Univariate and multivariate analysis revealed that there were no significant correlation of pts age, the response to prior docetaxel therapy or cycles of docetaxel therapy with shorter OS. Conclusions: These results suggest that cabazitaxel is a safe and effective treatment option for mCRPC pts who progress after docetaxel and indicate that the introduction of cabazitaxel for mCRPC pts could result in oncological outcomes without any association with ptsu2019s age and the profiles of previous docetaxel therapy.
Author : Fred Saad
Publisher : Springer
ISBN 13 : 1493911767
Total Pages : 336 pages
Book Rating : 4.4/5 (939 download)
Download or read book Management of Castration Resistant Prostate Cancer written by Fred Saad and published by Springer. This book was released on 2014-08-20 with total page 336 pages. Available in PDF, EPUB and Kindle. Book excerpt: This volume provides new data about the molecular biology of CRPC and a review of the definition, staging and prognostic factors that define CRPC. The book features an in depth review of proven therapeutic options, including bone targeted therapies, immunotherapy, chemotherapy and hormonal based therapies. Combination therapy as well as novel targeted approaches presently under investigations are also reviewed. The text provides up to date guidelines and algorithms for the management of CRPC based on international guidelines presently available as well as evidence based medicine. As a concise yet comprehensive summary of the current status of the field, Management of Castration Resistant Prostate Cancer serves as a very useful resource for physicians and researchers dealing with this challenging malignancy.
Author : Stéphane Oudard
Publisher :
ISBN 13 :
Total Pages : pages
Book Rating : 4.:/5 (111 download)
Download or read book Cabazitaxel Versus Docetaxel as First-line Therapy for Patients with Metastatic Castration-resistant Prostate Cancer written by Stéphane Oudard and published by . This book was released on 2017 with total page pages. Available in PDF, EPUB and Kindle. Book excerpt:
Author : Pamela Ellsworth
Publisher : Jones & Bartlett Learning
ISBN 13 : 1284081788
Total Pages : 95 pages
Book Rating : 4.2/5 (84 download)
Download or read book 20 Questions and Answers about Metastatic Castration-Resistant Prostate Cancer (mCRCP) written by Pamela Ellsworth and published by Jones & Bartlett Learning. This book was released on 2014-09-26 with total page 95 pages. Available in PDF, EPUB and Kindle. Book excerpt: Based on Jones & Bartlett Learning's acclaimed 100 Questions & Answers series, 20 Questions and Answers about Metastatic Castration-Resistant Prostate Cancer (mCRCP) provides authoritative and practical answers to the most common questions asked by men who have been diagnosed with prostate cancer which has proven to be resistant to initial therapies. Providing both doctor and patient perspectives, this easy-to-read book is a comprehensive guide to metastatic castration resistant prostate cancer, and is must-have for patients as well as their caregivers. Written by Dr. Pamela Ellsworth, a prominent urologist and best-selling author, 20 Questions and Answers about Metastatic Castration-Resistant Prostate Cancer (mCRCP) is an invaluable resource for anyone who has been impacted by prostate cancer.
Author : Hung-Ming Lam
Publisher : Frontiers Media SA
ISBN 13 : 2889662780
Total Pages : 99 pages
Book Rating : 4.8/5 (896 download)
Download or read book Response and Resistance in Castration-Resistant Prostate Cancer written by Hung-Ming Lam and published by Frontiers Media SA. This book was released on 2020-12-24 with total page 99 pages. Available in PDF, EPUB and Kindle. Book excerpt: This eBook is a collection of articles from a Frontiers Research Topic. Frontiers Research Topics are very popular trademarks of the Frontiers Journals Series: they are collections of at least ten articles, all centered on a particular subject. With their unique mix of varied contributions from Original Research to Review Articles, Frontiers Research Topics unify the most influential researchers, the latest key findings and historical advances in a hot research area! Find out more on how to host your own Frontiers Research Topic or contribute to one as an author by contacting the Frontiers Editorial Office: frontiersin.org/about/contact.
Author : Mario A. Eisenberger
Publisher :
ISBN 13 :
Total Pages : pages
Book Rating : 4.:/5 (11 download)
Download or read book Phase III Study Comparing a Reduced Dose of Cabazitaxel (20 Mg/m2) and the Currently Approved Dose (25 Mg/m2) in Postdocetaxel Patients with Metastatic Castration-resistant Prostate Cancer PROSELICA written by Mario A. Eisenberger and published by . This book was released on 2017 with total page pages. Available in PDF, EPUB and Kindle. Book excerpt:
Author : Tom Brody
Publisher : Academic Press
ISBN 13 : 0128146486
Total Pages : 671 pages
Book Rating : 4.1/5 (281 download)
Download or read book FDA's Drug Review Process and the Package Label written by Tom Brody and published by Academic Press. This book was released on 2017-12-01 with total page 671 pages. Available in PDF, EPUB and Kindle. Book excerpt: FDA's Drug Review Process and the Package Label provides guidance to pharmaceutical companies for writing FDA-submissions, such as the NDA, BLA, Clinical Study Reports, and Investigator's Brochures. The book provides guidance to medical writers for drafting FDA-submissions in a way more likely to persuade FDA reviewers to grant approval of the drug. In detail, the book reproduces data on efficacy and safety from one hundred different FDA-submissions (NDAs, BLAs). The book reproduces comments and complaints from FDA reviewers regarding data that are fragmentary, ambiguous, or that detract from the drug's approvability, and the book reveals how sponsors overcame FDA's concerns and how sponsors succeeded in persuading FDA to grant approval of the drug. The book uses the most reliable and comprehensive source of information available for writing FDA-submissions, namely text and data from NDAs and BLAs, as published on FDA's website. The source material for writing this book included about 80,000 pages from FDA's Medical Reviews, FDA's Clinical Pharmacology Reviews, and FDA's Pharmacology Reviews, from one hundred different NDAs or BLAs for one hundred different drugs. Each chapter focuses on a different section of the package label, e.g., the Dosage and Administration section or the Drug Interactions section, and demonstrates how the sponsor's data supported that section of the package label. Reveals strategies for winning FDA approval and for drafting the package label Examples are from one hundred FDA-submissions (NDAs, BLAs) for one hundred different drugs, e.g., for oncology, metabolic diseases, autoimmune diseases, and neurological diseases This book uses the most reliable and comprehensive source of information available for writing FDA-submissions, namely, the data from NDAs and BLAs as published on FDA's website at the time FDA grants approval to the drug
Author : Emmanuel S. Antonarakis
Publisher :
ISBN 13 :
Total Pages : pages
Book Rating : 4.:/5 (119 download)
Download or read book Randomized, Noncomparative, Phase II Trial of Early Switch from Docetaxel to Cabazitaxel Or Vice Versa, with Integrated Biomarker Analysis, in Men with Chemotherapy-naïve, Metastatic, Castration-resistant Prostate Cancer written by Emmanuel S. Antonarakis and published by . This book was released on 2017 with total page pages. Available in PDF, EPUB and Kindle. Book excerpt:
Author : S. Hotte
Publisher :
ISBN 13 :
Total Pages : 19 pages
Book Rating : 4.:/5 (951 download)
Download or read book The Use of Cabazitaxel in Men with Castrate Resistant Metastatic Prostate Cancer Previously Treated with Docetaxel written by S. Hotte and published by . This book was released on 2011 with total page 19 pages. Available in PDF, EPUB and Kindle. Book excerpt:
Download or read book Health Technology Assessment of Four Drugs for Patients with Metastatic Castration Resistant Prostate Cancer written by and published by . This book was released on 2016 with total page pages. Available in PDF, EPUB and Kindle. Book excerpt:
Author : National Institute for Health and Clinical Excellence (Great Britain)
Publisher :
ISBN 13 :
Total Pages : 48 pages
Book Rating : 4.:/5 (16 download)
Download or read book Cabazitaxel for Hormone-refractory Metastatic Prostate Cancer Previously Treated with a Docetaxel-containing Regimen written by National Institute for Health and Clinical Excellence (Great Britain) and published by . This book was released on 2012 with total page 48 pages. Available in PDF, EPUB and Kindle. Book excerpt:
Author : Shelly Rainforth Collins
Publisher : Elsevier Health Sciences
ISBN 13 : 0323825168
Total Pages : 1408 pages
Book Rating : 4.3/5 (238 download)
Download or read book Elsevier's 2022 Intravenous Medications - E-Book written by Shelly Rainforth Collins and published by Elsevier Health Sciences. This book was released on 2021-04-16 with total page 1408 pages. Available in PDF, EPUB and Kindle. Book excerpt: Find the essential information you need to safely administer more than 400 intravenous drugs! For more than 45 years, Gahart’s Intravenous Medications: A Handbook for Nurses and Health Professionals has been a trusted resource for comprehensive drug coverage, unparalleled accuracy, and an intuitive quick-access format. In addition to updated drug interactions, precautions, alerts, and patient teaching instructions for all existing IV drugs, the 2022 edition includes approximately 10 new monographs of the most recent IV drugs to be approved by the FDA. Administering intravenous drugs is a critical task — inaccurate or out-of-date information is not an option. Known as the #1 IV drug handbook on the market, and with its history of impeccable accuracy, Gahart’s annual publication gives you the extra confidence and guidance you need to safely and effectively treat patients. Monographs on more than 400 IV drugs offer an impressive breadth of coverage that goes well beyond any comparable drug reference. Updated annual publication prevents you from referencing outdated information. Additional drug monographs are provided on the companion Evolve website. 45-year history of impeccable accuracy reinforces the importance of safe IV drug administration. Perfect depth of information equips you with everything that is needed for safe administration of IV drugs — nothing more, nothing less. Proven, clinically optimized format keeps all dosage information for each drug on either a single page or a two-page spread to prevent hand contamination by having to turn a page. Highlighted Black Box Warnings and relevant content make locating critical information fast and easy. Special circumstances in blue-screened text call attention to important circumstances that may not warrant Black Box Warnings. Life-stage dosage variances are highlighted for geriatric, pediatric, infant, and neonatal patients. Dilution and dosage charts within monographs provide quick access to essential clinical information. Convenient, alphabetical format organizes all drug monographs by generic name, allowing you to find any drug in seconds. NEW! Drug monographs for newly approved drugs by the FDA provide you with the most current drug information. Updates on drug interactions, precautions, alerts, and more have been made throughout the guide to reflect all changes to existing medications.
